Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Frontiers in Oncology|August 22, 2022
Associations of clinical and circulating metabolic biomarkers with low physical fitness and function in adults with chronic lymphocytic leukemiaAndrea Sitlinger, Michael A Deal, Erwin Garcia, et al.
Cells|June 2, 2021
Physiological Fitness and the Pathophysiology of Chronic Lymphocytic Leukemia (CLL)Andrea Sitlinger, Michael A Deal, Erwin Garcia, et al.
Contemporary Clinical Trials|May 3, 2026
Hybrid-delivered cognitive behavioral symptom management and activity coaching intervention for patients following hematopoietic stem cell transplant or CAR T-cell therapy: Protocol of a randomized controlled trialPatricia B Pedreira, Tamara J Somers, Hannah M Fisher, et al.
Research and Practice in Thrombosis and Haemostasis|May 31, 2024
An epidemiologic study comparing cancer- and noncancer-associated venous thromboembolism in a racially diverse Southeastern United States countyAndrew M Peseski, Sargam Kapoor, Maragatha Kuchibhatla, et al.
JACC. Cardiooncology|July 12, 2022
Cardiometabolic Comorbidities in Cancer Survivors: <i>JACC: CardioOncology</i> State-of-the-Art ReviewLeah L Zullig, Anthony D Sung, Michel G Khouri, et al.
Journal of Medical Education and Curricular Development|August 6, 2024
Educating Hematology-Oncology Fellows About How to Communicate with Patients About Clinical Trials: A Needs AssessmentNaomi D Parker, Martina C Murphy, Susan Eggly, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2021
The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity ModelMax J Gordon, Andy Kaempf, Andrea Sitlinger, et al.
Blood Advances|August 26, 2020
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agentsLindsey E Roeker, Peter Dreger, Jennifer R Brown, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 13, 2026
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026William G Wierda, Jennifer Brown, Jeremy S Abramson, et al.
Blood|December 1, 2020
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapyAnthony R Mato, Nilanjan Ghosh, Stephen J Schuster, et al.
Pageof 3